Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Equity Average (2020 - 2025)

Historic Equity Average for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$4.0 million.

  • Insight Molecular Diagnostics' Equity Average fell 12498.3% to -$4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.0 million, marking a year-over-year decrease of 12498.3%. This contributed to the annual value of $4.1 million for FY2024, which is 8503.65% down from last year.
  • Insight Molecular Diagnostics' Equity Average amounted to -$4.0 million in Q3 2025, which was down 12498.3% from $5.7 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Equity Average's 5-year high stood at $104.6 million during Q2 2021, with a 5-year trough of -$4.0 million in Q3 2025.
  • Moreover, its 5-year median value for Equity Average was $29.0 million (2023), whereas its average is $39.5 million.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 17459.92% in 2021, then plummeted by 12498.3% in 2025.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Equity Average stood at $82.3 million in 2021, then crashed by 32.46% to $55.6 million in 2022, then tumbled by 47.79% to $29.0 million in 2023, then plummeted by 104.42% to -$1.3 million in 2024, then plummeted by 215.96% to -$4.0 million in 2025.
  • Its Equity Average stands at -$4.0 million for Q3 2025, versus $5.7 million for Q2 2025 and -$1.0 million for Q1 2025.